Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value - PubMed (original) (raw)

. 2010 Sep 23;116(12):2122-6.

doi: 10.1182/blood-2009-11-250878. Epub 2010 Jun 10.

Affiliations

• PMID: 20538800
• DOI: 10.1182/blood-2009-11-250878

Free article

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

Saman Abbas et al. Blood. 2010.

Free article

Abstract

Somatic mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) were recently demonstrated in acute myeloid leukemia (AML), but their prevalence and prognostic impact remain to be explored in large extensively characterized AML series, and also in various other hematologic malignancies. Here, we demonstrate in 893 newly diagnosed cases of AML mutations in the IDH1 (6%) and IDH2 (11%) genes. Moreover, we identified IDH mutations in 2 JAK2 V617F myeloproliferative neoplasias (n = 96), a single case of acute lymphoblastic leukemia (n = 96), and none in chronic myeloid leukemias (n = 81). In AML, IDH1 and IDH2 mutations are more common among AML with normal karyotype and NPM1(mutant) genotypes. IDH1 mutation status is an unfavorable prognostic factor as regards survival in a composite genotypic subset lacking FLT3(ITD) and NPM1(mutant). Thus, IDH1 and IDH2 mutations are common genetic aberrations in AML, and IDH1 mutations may carry prognostic value in distinct subtypes of AML.

PubMed Disclaimer

Similar articles

• Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
  Chotirat S, Thongnoppakhun W, Promsuwicha O, Boonthimat C, Auewarakul CU. Chotirat S, et al. J Hematol Oncol. 2012 Mar 7;5:5. doi: 10.1186/1756-8722-5-5. J Hematol Oncol. 2012. PMID: 22397365 Free PMC article.
• IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
  Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K. Paschka P, et al. J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21. J Clin Oncol. 2010. PMID: 20567020
• [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
  Jia ZX, Zhou M, Chao HY, Lu XZ, Zhang R, Cen L, Xiao R, Jiang NK. Jia ZX, et al. Zhonghua Xue Ye Xue Za Zhi. 2012 May;33(5):397-401. Zhonghua Xue Ye Xue Za Zhi. 2012. PMID: 22781800 Chinese.
• IDH mutations in acute myeloid leukemia.
  Rakheja D, Konoplev S, Medeiros LJ, Chen W. Rakheja D, et al. Hum Pathol. 2012 Oct;43(10):1541-51. doi: 10.1016/j.humpath.2012.05.003. Epub 2012 Aug 20. Hum Pathol. 2012. PMID: 22917530 Review.
• DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.
  Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE, Boyiadzis M. Im AP, et al. Leukemia. 2014 Sep;28(9):1774-83. doi: 10.1038/leu.2014.124. Epub 2014 Apr 4. Leukemia. 2014. PMID: 24699305 Free PMC article. Review.

Cited by

• IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
  Yang H, Ye D, Guan KL, Xiong Y. Yang H, et al. Clin Cancer Res. 2012 Oct 15;18(20):5562-71. doi: 10.1158/1078-0432.CCR-12-1773. Clin Cancer Res. 2012. PMID: 23071358 Free PMC article. Review.
• The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.
  Rakheja D, Medeiros LJ, Bevan S, Chen W. Rakheja D, et al. Front Oncol. 2013 Jul 2;3:169. doi: 10.3389/fonc.2013.00169. eCollection 2013. Front Oncol. 2013. PMID: 23847760 Free PMC article.
• Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.
  Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A, Hricik T, Heguy A, Hedvat C, Gönen M, Kantarjian H, Levine RL, Abdel-Wahab O, Verstovsek S. Zhang SJ, et al. Blood. 2012 May 10;119(19):4480-5. doi: 10.1182/blood-2011-11-390252. Epub 2012 Mar 19. Blood. 2012. PMID: 22431577 Free PMC article.
• Rescue of TCA Cycle Dysfunction for Cancer Therapy.
  Marquez J, Flores J, Kim AH, Nyamaa B, Nguyen ATT, Park N, Han J. Marquez J, et al. J Clin Med. 2019 Dec 6;8(12):2161. doi: 10.3390/jcm8122161. J Clin Med. 2019. PMID: 31817761 Free PMC article. Review.
• Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience.
  Ambinder A, Smith M, Tsai HL, Varadhan R, DeZern A, Dalton W, Gocke C, Webster J, Gondek L, Gojo I, Ali SA, Huff CA, Swinnen L, Wagner-Johnston N, Showel M, Prince G, Borrello I, Bolaños-Meade J, Luznik L, Jain T, Imus P, Fuchs E, Ambinder R, Gladstone DE, Levis M, Jones R, Ghiaur G, Smith BD. Ambinder A, et al. Clin Lymphoma Myeloma Leuk. 2022 Apr;22(4):260-269. doi: 10.1016/j.clml.2021.09.022. Epub 2021 Oct 9. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34750086 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal